All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for INDIVIOR INC. · pharmaceutical company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 19, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 4

Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 5342
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
S 2354
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 2

Pharmacy

Issues related to overdose reversal products including Naloxone; FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.5342/S.2354).

Medicare/Medicaid

Medicaid policies related to substance use disorder; H.R.1, One Big Beautiful Bill Act (P.L.119-21).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.